The Quantellect read.As of Nov 19, 2026, 6 active firms cover Relmada Therapeutics Inc: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $8.00 to $19.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $12.33 sits 332% above the current $2.85. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.14 next quarter toward $-0.41 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$12.33
+332.0% upside
Average target across 6 active firms as of Nov 19, 2026 vs $2.86 current
Highest Target$19.00
Average Target$12.33
Lowest Target$8.00
Detailed analyst forecasts for RLMD
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 6 of 6 active firms rate RLMD a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RLMD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.18 – $-0.11 · 2 analysts
Next period, 2 analysts expect Relmada Therapeutics Inc to earn $-0.14 a share (range $-0.18 – $-0.11), versus — a year earlier. Full-year consensus is $-0.41, growing to $-0.41 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Relmada Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RLMD.
#1
Andrew Berens
Leerink Partners · Rank #162
Buy
$8.00+180.2% to target
Overall win rate
53%
+ Follow
#2
Marc Goodman
Leerink Partners · Rank #251
Neutral
$1.00-65.0% to target
Overall win rate
46%
+ Follow
#3
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$12.00+320.3% to target
Overall win rate
39%
+ Follow
#4
UE
Uy Ear
Mizuho
Buy
$19.00+565.5% to target
Coverage
—
+ Follow
#5
FH
Farzin Haque
Jefferies
Buy
$9.00+215.2% to target
Coverage
—
+ Follow
RLMD stock forecast FAQ
What is RLMD's average 12-month price target?+
The 6 active firms with a live target average $12.33 for Relmada Therapeutics Inc over the next 12 months, ranging from a $19.00 high to a $8.00 low, as of Nov 19, 2026.
Is RLMD stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RLMD?+
The Street-high target is $19.00 (Mizuho), and the Street-low is $8.00 (Leerink Partners). The average of all 6 active-firm targets is $12.33.
How many active Wall Street firms cover RLMD?+
6 active firms have a recognized rating on Relmada Therapeutics Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RLMD?+
Among analysts who currently cover RLMD, Andrew Berens of Leerink Partners has the strongest overall Quantellect track record (Rank #162). Their current call is Buy with a $8.00 target.
What is Relmada Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.18 – $-0.11) across 2 analysts. Full-year EPS is projected at $-0.41, rising to $-0.41 the following year.
How much revenue is Relmada Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading RLMD lately?+
As of Nov 19, 2026, 6 of 6 active firms rate RLMD a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RLMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.